Abstract:Background: Liver cancer is one of common types of cancer with poor prognosis and limited therapies. Heat shock proteins (HSP) are molecular chaperones that have important roles in tumorigenesis, and emerging as therapeutic targets. Artemisinin and rhein are natural agents from Artemisia annua L. and Rheum undulatum L., respectively. Both rhein and artemisinin have anticancer effects; however, the molecular targets of rhein remain to be identified. It is also unclear whether rhein can synergize with artemisinin derivatives to inhibit liver cancer.Purpose: We aim to identify the targets of rhein in the treatment of hepatocarcinoma and determine the effects of combining rhein and artemisinin derivatives on liver cancer cells. Methods: The targets of rhein were detected by mass spectrometry and validated by rheinproteins interaction assays. The effects of rhein on the chaperone activity of HSP72/HSC70/GRP78 were determined by luciferase refolding assays. Cell viability and apoptosis were determined by CCK8 and flow cytometry assays. For in vivo study, xenograft tumor models were established and treated with rhein and artesunate. Tumor growth was monitored regularly. Results: Mass spectrometry analysis of rheinbinding proteins in HepG2 cells revealed that HSP72, HSC70 and GRP78 were more profoundly pulled down by rhein-crosslinked sepharose 4B beads compared to the control beads. Further experiments demonstrated that rhein directly interacted with HSP72/HSC70/GRP78 proteins, and inhibit their activity of refolding denatured luciferase. Meanwhile, rhein induced proteasomal degradation of HIF1 alpha and beta-catenin. Artesunate or dihydroartemisinin in combination with knockdown of both HSP72 and HSC70 significantly inhibited cell viability. The HSP70/HSC70/GRP78 inhibitors VER-155,008 and rhein phenocopied HSP72/HSC70 knockdown, synergizing with artesunate or dihydroartemisinin to inhibit hepatocarcinoma cell viability. Combinatorial treatment with rhein and artemisinin derivatives significantly induced hepatocarcinoma cell apoptosis, and inhibited tumor growth in vivo. Conclusions: The current study demonstrates that rhein is a novel HSP72/HSC70/GRP78 inhibitor that suppresses the chaperone activity of HSP70s. Dual inhibition of HSP72 and HSC70 can enhance the sensitivity of hepatocarcinoma cells to artemisinin derivatives. Combined treatment with artemisinin derivative and rhein significantly inhibits hepatocarcinoma. Artemisinin derivatives in combination with dual inhibition of HSP72 and HSC70 represents a new approach to improve cancer therapy.

Mitochondria-Targeting Artesunate-Rhein Conjugates: Linker-Modulated Cell-Permeability, Heme-Affinity and Anticancer Activity

A Mitochondria-Targeting Artemisinin Derivative with Sharply Increased Antitumor but Depressed Anti-Yeast and Anti-Malaria Activities

Mechanism-Guided Design and Synthesis of a Mitochondria-Targeting Artemisinin Analogue with Enhanced Anticancer Activity.

Development of artesunate intelligent prodrug liposomes based on mitochondrial targeting strategy

Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties

Mitochondria-targeted artesunate conjugated cyclometalated iridium(iii) complexes as potent anti-HepG2 hepatocellular carcinoma agents.

Ph-Dependent Reversibly Activatable Cell-Penetrating Peptides Improve the Antitumor Effect of Artemisinin-Loaded Liposomes.

Artemisinin and AIEgen Conjugate for Mitochondria-Targeted and Image-Guided Chemo- and Photodynamic Cancer Cell Ablation

GPX4 Inhibition Synergistically Boosts Mitochondria Targeting Nanoartemisinin-Induced Apoptosis/ferroptosis Combination Cancer Therapy.

The Conjugate of Rhein–Artesunate for Inducing Immunogenic Cell Death to Prepare Cancer Vaccine and Suppress Tumor Growth

Liensinine Inhibits Mitophagy to Potentiate Mitochondria-Targeting Artemisinin-Loaded Polymer Nanostructures for Breast Cancer Therapy

Fluorescent Coumarin-Artemisinin Conjugates As Mitochondria-Targeting Theranostic Probes for Enhanced Anticancer Activities

Enhanced Fe(II)-artemisinin-mediated chemodynamic therapy with efficient Fe(III)/Fe(II) conversion circulation for cancer treatment

Synthesis and Biological Evaluation of a Novel Artesunate-Podophyllotoxin Conjugate As Anticancer Agent.

Targeting HSP70 Chaperones by Rhein Sensitizes Liver Cancer to Artemisinin Derivatives

Facilitated Drug Repurposing with Artemisinin-Derived PROTACs: Unveiling PCLAF as a Therapeutic Target

Methemoglobin As A Redox-Responsive Nanocarrier to Trigger the in Situ Anticancer Ability of Artemisinin

Dihydroartemisinin and transferrin dual-dressed nano-graphene oxide for a pH-triggered chemotherapy

A metal-organic framework-based redox homeostasis disruptor selectively potentiate the cytotoxicity of dihydroartemisinin for cancer therapy

Enhanced delivery of artesunate by stimuli-responsive polymeric micelles for lung tumor therapy

Therapeutic Potentials and Mechanisms of Artemisinin and its Derivatives for Tumorigenesis and Metastasis.